Canine Arthritis Treatment Market Analysis

  • Report ID: 2972
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Canine Arthritis Treatment Segmentation

The market is segmented by type into joint instability, joint incongruity, osteochondrosis, and others out of which, the osteochondrosis segment is anticipated to hold the largest share in the market during the forecast period on account of highest prevalence of this disease, as it is most common in dogs above 8 years of age. On the basis of diagnosis, the market is segmented into X-ray, arthroscopy, MRI, and others, out of which, the X-ray segment is expected to garner highest revenue, owing to the ease of getting X-ray imaging of pets, as compared to other methods

Our in-depth analysis of the global market includes the following segments:

           Type

  • Joint Instability

  • Joint Incongruity

  • Osteochondrosis

  • Others

             Diagnosis

  • X-ray

  • Arthroscopy

  • MRI

  • Others

             Treatment

  • Joint Supplements

  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

  • Physiotherapy

  • Acupuncture

  • Surgery

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of canine arthritis treatment is evaluated at USD 2.66 billion.

Canine Arthritis Treatment Market size was over USD 2.56 billion in 2024 and is poised to exceed USD 4.59 billion by 2037, growing at over 4.6% CAGR during the forecast period i.e., between 2025-2037.

North America industry is set to dominate majority revenue share by 2037, on the back of high pet population, in the U.S.

The major players in the market are Boehringer Ingelheim USA Corporation, Norbrook Laboratories Limited, American Regent, Inc., Vetoquinol S.A., Ceva Santé Animale, Elanco Animal Health Inc., Hill's Pet Nutrition, Inc., and others.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos